COMMUNIQUÉS West-GlobeNewswire

MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
05/11/2025
Conference call today at 9:00 am ET Q3 2025 revenues of $82.1M, +17% v. Q3 2024 YTD 2025 revenues of $237.0M, +14% v. YTD 2024 Completed acquisition of scPharmaceuticals on October 7, accelerating MannKind’s revenue [...]
Curonix Strengthens Executive Leadership with Appointment of Leading Medical Device Executive Russell Fleeger as Chief Financial Officer to Drive Next Stage of Growth
05/11/2025
POMPANO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Curonix LLC (“Curonix” or the “Company”), a medical technology company dedicated to developing and commercializing innovative therapies to relieve chronic pain, [...]
Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights
05/11/2025
FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved comparability [...]
MediWound to Report Third Quarter 2025 Financial Results
05/11/2025
MediWound to Report Third Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time YAVNE, Israel, November 5, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “ [...]
Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
05/11/2025
Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the analyses of [...]
Altimmune to Participate in Two Upcoming Investor Conferences
05/11/2025
GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, [...]
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
05/11/2025
BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) [...]
Crescent Biopharma to Present at November Investor Conferences
05/11/2025
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer [...]
Rezolute to Host Virtual Investor Event on Ersodetug Development Program
05/11/2025
Webcast scheduled for Monday, November 10 at 12:00 pm EST REDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on [...]
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
05/11/2025
HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of [...]
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
05/11/2025
ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology (ASN) Kidney Week [...]
Telix to Participate in UBS and Jefferies Global Healthcare Conferences
05/11/2025
MELBOURNE, Australia and INDIANAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will participate in the upcoming UBS Global Healthcare Conference in Palm Beach, FL [...]
Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies
05/11/2025
DSAP is a premalignant, progressive disease characterized by numerous expanding lesions which significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. [...]
Immuron IMM-529 IND approved by FDA
05/11/2025
Key Points Immuron receives U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application and clinical study may proceed FDA assigned an IND number (032095) for the IMM-529 [...]
RadNet Expands Comprehensive Remote Scanning Offering with Acquisition of Alpha RT’s Assets
05/11/2025
RadNet subsidiary DeepHealth to commercialize a robust end-to-end remote-imaging offering featuring both TechLive™ remote scanning technology and Alpha RT’s MRI staffing services and training programs LOS ANGELES, Nov. [...]
Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
05/11/2025
Marks Aclarion’s first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgery Experiencing strong commercial traction in UK as first market [...]
Maple acquires Beyond ADHD to expand responsible ADHD and mental health care across Canada
05/11/2025
Acquisition strengthens access to clinically led virtual ADHD and mental health programs nationwide TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Maple, Canada’s leading virtual care company, today announced the [...]
Oculis to Participate in Upcoming November Investor Conferences
05/11/2025
ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical [...]
Oculis to Participate in Upcoming November Investor Conferences
05/11/2025
ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical [...]

Pages

Other news

Promaxo Announces Closing of Series C Financing and $100M Credit Facility

The growth capital will expand manufacturing capacity, reduce backlog, and support new regulatory filings

ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update

WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp.

BreathiZen Introduces BreathiZen Spray - A New Multi-Ingredient Dietary Supplement For Your Respiratory Wellness

BreathiZen is a once-daily oral spray that brings together botanical extracts, an enzyme preparation, and selected nutrients in a 60 ml bottle designed to fit easily into an adult wellness routine.

New York, Oct. 22, 2026 (GLOBE NEWSWIRE) --

RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

Company to host conference call on November 5, 2026, at 4:30 p.m. ET

BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET

PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc.

Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment

Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc.